After TROP2 and HER2, Is B7-H3 the Next Big ADC Target?

Antibody-drug conjugates (ADCs) have become the hottest modality in oncology. The template was Enhertu, AstraZeneca and Daiichi Sankyo‘s HER2-directed ADC, which turned a modest drug class into…